Used in the treatment of inflammatory and autoimmune diseases by blocking the C5a receptor (C5aR1), this antibody inhibits the pro-inflammatory effects of the complement system. It is particularly effective in conditions where excessive complement activation leads to tissue damage, such as in rheumatoid arthritis, lupus nephritis, and certain vasculitides. It has also shown promise in reducing inflammation in neurodegenerative diseases and ischemia-reperfusion injury. Due to its high specificity, it helps minimize off-target effects, making it a valuable therapeutic candidate in clinical development for chronic inflammatory conditions.